WINSTON & STRAWN LLP

NORTH AMERICA SOUTH AMERICA EUROPE ASIA

200 Park Avenue
New York, NY 10166
T +1 (212) 294-6700
F +1 (212) 294-4700

ASHLEY GRAHAM
Associate
212-294-1727
AGraham@winston.com

November 30, 2023

Erica R. Sutter
Fenwick & West LLP
902 Broadway, Suite 14
New York, NY 10010
esutter@fenwick.com

Re: *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 3038, No. 22-cv-294-CFC (D. Del.) (consolidated)

Dear Counsel:

Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (collectively, "DRL") hereby produce via FTP DRL's production of documents bearing Bates numbers DRL_0158219-DRL_0158307. The documents can be accessed via the following link:

- FTP Link: [redacted]
- FTP Password: [redacted]

Please note that these documents have been marked "Confidential" pursuant to the Protective Order Governing the Collection and Production of Documents and Electronically Stored Information entered by the Court on August 08, 2022 (the "Protective Order") (Dkt. 51). To the extent that any privileged documents are inadvertently produced, DRL does not waive its right to retrieve them.

Best regards,

/s/ *Ashley Graham*
Ashley Graham

Cc: Counsel of record

From: Huang, Karen (Perkins Coie) <KHuang@perkinscoie.com>
Sent: Friday, October 27, 2023 11:22 AM
To: jblumenfeld@morrisnichols.com; began@morrisnichols.com; tmurray@morrisnichols.com; jfc@schraderlaw.com; Laura Moran; Robert Counihan; Jeff Oelke; Ryan Johnson; Erica Sutter; Olivia Wheeling; Silvia Medina; Vanessa Park-Thompson; Allie Cohen Dolloff; Ryan Haddad; Michael Yoon; Retley Locke
Cc: Semaglutide-Ozempic@perkinscoie.com; stamoulis@swdelaw.com; weinblatt@swdelaw.com
Subject: In re: Ozempic (Semaglutide) Patent Litigation (Nos. 22-MD-3038, 22-1040)

**** EXTERNAL EMAIL ****

Counsel,

Documents numbered MPI-SM00046891 - MPI-SM00046930 and MPI-8MG-SM0008670 - MPI-8MG-SM0008712 will be produced by FTP at the following links:

[redacted]

Password for the FTPs and productions will follow separately.

Please note that these documents have been designated as "Confidential Information – Subject to Protective Order" pursuant to the Stipulated Protective Order. Please treat these documents accordingly.

Regards,

Karen Huang | **Perkins Coie LLP**
SENIOR PARALEGAL
1120 N.W. Couch Street Tenth Floor
Portland, OR 97209-4128
D. +1.503.727.2260
F. +1.503.727.2222
E. KHuang@perkinscoie.com

NOTICE: This communication may contain privileged or other confidential information. If you have received it in error, please advise the sender by reply email and immediately delete the message and any attachments without copying or disclosing the contents. Thank you.

From: West, Christopher W. <christopher.west@katten.com>
Sent: Tuesday, November 21, 2023 12:25 PM
To: Erica Sutter; Laura Moran; farnan@rlf.com; Caras, Valerie A.; FW Sema
Cc: Ferenc, Christopher B.; Sodikoff, Brian
Subject: RE: Document production: In re: Ozempic (Semaglutide) Patent Litigation, MDL No. 3038, C.A. No. 22-cv-294-CFC (CONSOLIDATED) (D. Del.)

**** EXTERNAL EMAIL ****

Hi Erica,

Sun is providing a production via secure FTP today, bearing the Bates Range: SUN-SEMA_0249229 - SUN-SEMA_0249453. Passwords to access the site and open this production will follow separately. The link to access the documents is:

[redacted]

Login: [redacted]

If you have any issues downloading the documents, please contact us.

Best regards,

Chris

Christopher W. West, Ph.D.
Counsel

Katten
Katten Muchin Rosenman LLP
550 S. Tryon Street, Suite 2900 | Charlotte, NC 28202-4213
direct +1.704.344.3098 mobile +1.707.315.8386
christopher.west@katten.com | katten.com

==========
CONFIDENTIALITY NOTICE:
This electronic mail message and any attached files contain information intended for the exclusive
use of the individual or entity to whom it is addressed and may contain information that is
proprietary, privileged, confidential and/or exempt from disclosure under applicable law. If you
are not the intended recipient, you are hereby notified that any viewing, copying, disclosure or
distribution of this information may be subject to legal restriction or sanction. Please notify
the sender, by electronic mail or telephone, of any unintended recipients and delete the original
message without making any copies.
==========
NOTIFICATION: Katten Muchin Rosenman LLP is an Illinois limited liability partnership that has

Novo Nordisk Exhibit 2020
Sun Pharm Indus. Ltd. v. Novo Nordisk A/S
IPR2024-00107
Page 00003

elected to be governed by the Illinois Uniform Partnership Act (1997).
==========

Novo Nordisk Exhibit 2020
Sun Pharm Indus. Ltd. v. Novo Nordisk A/S
IPR2024-00107
Page 00004

Taft/

111 East Wacker, Suite 2800 / Chicago, Illinois 60601
Tel: 312.527.4000 / Fax: 312.527.4011
www.taftlaw.com

Patricia A. Skinner
Direct Dial: (312) 836-4070
E-Mail: pskinner@taftlaw.com

October 5, 2023

VIA ELECTRONIC MAIL & SECURE SEND

Erica Sutter
FENWICK & WEST LLP
902 Broadway, Suite 14
New York, New York 10010-6035
(212) 430-2600

Re: ***Novo Nordisk Inc., et al. v. Rio Biopharmaceuticals, Inc., et al.*** **22-cv-00294-CFC (D. Del.)**

Dear Ms. Sutter:

Rio Biopharmaceuticals, Inc. has posted a production bearing Bates numbers RIO-SEM-00041658 through RIO-SEM-00048828 to a secure site for your download. Many of these documents are marked Highly Confidential Subject to Protective Order and should be treated accordingly. The login and password credentials for accessing the documents will be forwarded by separate email and the documents will only be available through October 13, 2023. If you have any questions or concerns regarding this production, please direct these to me at the above telephone number or email address.

Sincerely,

/s/ Patricia A. Skinner

Patricia A. Skinner

cc: Stephen R. Auten
Richard T. Ruzich
Philip Y. Kouyoumdjian
Jaimin Shah
Kenneth L. Dorsney
Attached Service List

Service List

FENWICK & WEST LLP
902 Broadway, Suite 14
New York, New York 10010-6035
(212) 430-2600

Jeffrey J. Oelke	joelke@fenwick.com
Ryan P. Johnson	ryan.johnson@fenwick.com
Robert E. Counihan	rcounihan@fenwick.com
Laura T. Moran	laura.moran@fenwick.com
Erica R. Sutter	esutter@fenwick.com
Olivia Wheeling	owheeling@fenwick.com
Alexandra Cirra	acirra@fenwick.com
	FW-Sema@fenwick.com

Jack B. Blumenfeld (#1014)
Brian Egan
Travis Murray
MORRIS, NICHOLS, ARSHT & TUNNELL LLP
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com
tmurray@morrisnichols.com

Locke Lord LLP

111 South Wacker Drive
Suite 4100
Chicago, IL 60606
Telephone: 312-443-0700
Fax: 312-443-0336
www.lockelord.com

Jacob C. Britz
Direct Telephone: 312-443-0632
Direct Fax: 312-896-6333
jacob.britz@lockelord.com

July 25, 2023

BY EMAIL

Ryan P. Johnson
Fenwick and West LLP
902 Broadway, Suite 14
New York, NY 10010

Re: *In Re: Ozempic (Semaglutide) Patent Litigation*,
MDL No. 22-3038-CFC (D. Del.)

Dear Ryan:

Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited (collectively "Zydus") hereby produce documents bearing production numbers ZYDSEM_0031808 - ZYDSEM_0035995. Please note that these documents are being produced as "Confidential Information – Subject to Protective Order."

The documents are available for download on a secure, password-protected website located at:

URL: [redacted]

For security purposes, a separate e-mail will be sent to you containing the password required to access this production.

Zydus reserves the right to recall any document that is later determined to have been inadvertently produced. The production of these documents should not be construed as an admission that any document in this production is relevant or admissible.

If you have any questions, please do not hesitate to contact me.

Best regards,

LOCKE LORD LLP

Jacob C. Britz